BR0016817A - Combinações de um inibidor de quinase do receptor de tirosina com um composto orgânico capaz de se ligar à alfa1-glicoproteìna ácida - Google Patents

Combinações de um inibidor de quinase do receptor de tirosina com um composto orgânico capaz de se ligar à alfa1-glicoproteìna ácida

Info

Publication number
BR0016817A
BR0016817A BR0016817-3A BR0016817A BR0016817A BR 0016817 A BR0016817 A BR 0016817A BR 0016817 A BR0016817 A BR 0016817A BR 0016817 A BR0016817 A BR 0016817A
Authority
BR
Brazil
Prior art keywords
receptor
combinations
organic compound
binding
pdgf
Prior art date
Application number
BR0016817-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Carlo Gambacorti-Passerini
Philipp Lecoutre
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0016817A publication Critical patent/BR0016817A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR0016817-3A 1999-12-27 2000-12-22 Combinações de um inibidor de quinase do receptor de tirosina com um composto orgânico capaz de se ligar à alfa1-glicoproteìna ácida BR0016817A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI002711A ITMI992711A1 (it) 1999-12-27 1999-12-27 Composti organici
PCT/EP2000/013161 WO2001047507A2 (en) 1999-12-27 2000-12-22 Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound

Publications (1)

Publication Number Publication Date
BR0016817A true BR0016817A (pt) 2002-10-01

Family

ID=11384195

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016817-3A BR0016817A (pt) 1999-12-27 2000-12-22 Combinações de um inibidor de quinase do receptor de tirosina com um composto orgânico capaz de se ligar à alfa1-glicoproteìna ácida

Country Status (18)

Country Link
US (2) US20030125343A1 (enExample)
EP (1) EP1250140B1 (enExample)
JP (1) JP2003523325A (enExample)
CN (1) CN1304005C (enExample)
AR (1) AR030179A1 (enExample)
AT (1) ATE432069T1 (enExample)
AU (1) AU2171901A (enExample)
BR (1) BR0016817A (enExample)
CA (1) CA2394944A1 (enExample)
CO (1) CO5271710A1 (enExample)
DE (1) DE60042283D1 (enExample)
ES (1) ES2326307T3 (enExample)
HK (1) HK1050993A1 (enExample)
IT (1) ITMI992711A1 (enExample)
PE (1) PE20010991A1 (enExample)
PT (1) PT1250140E (enExample)
TW (1) TWI246917B (enExample)
WO (1) WO2001047507A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002223684A1 (en) * 2000-11-22 2002-06-03 Novartis Pharma Gmbh Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
EP1408978A4 (en) 2001-06-21 2005-07-13 Ariad Pharma Inc NOVEL PHENYLAMINO-PYRIMIDINES AND THEIR USE
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US7323469B2 (en) 2001-08-07 2008-01-29 Novartis Ag 7H-pyrrolo[2,3-d]pyrimidine derivatives
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
NZ552335A (en) * 2001-10-25 2008-11-28 Novartis Ag Combinations comprising a selective COX-2 inhibitor and a microtubule interfering agent
GB0201508D0 (en) 2002-01-23 2002-03-13 Novartis Ag Organic compounds
CA2479257A1 (en) * 2002-03-21 2003-10-02 Dana-Farber Cancer Institute, Inc. Inhibition of cell death responses induced by oxidative stress
AU2007201830C1 (en) * 2002-04-23 2017-09-07 Novartis Pharma Ag High drug load tablet
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20060052387A1 (en) * 2002-06-26 2006-03-09 Marsh Clay B Organic compounds
CA2498982A1 (en) * 2002-07-24 2004-01-29 Novartis Ag 4-(4-methylpiperazin-1-ylmethyl)-n-[4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating anaplastic thyroid cancer
AU2003250701A1 (en) * 2002-07-31 2004-02-16 Wayne R. Danter Protein tyrosine kinase inhibitors
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
CA2542007C (en) * 2002-10-09 2010-06-29 Wayne R. Danter Protein tyrosine kinase inhibitors
AU2003268185A1 (en) * 2003-08-25 2005-04-11 Dana-Farber Cancer Institute Inc. Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias
DE602004030265D1 (de) * 2003-09-19 2011-01-05 Novartis Ag Behandlung von gastrointestinalen stromatumoren mit imatinib und midostaurin
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
PL1720853T3 (pl) † 2004-02-11 2016-06-30 Natco Pharma Ltd Nowa odmiana polimorficzna metanosulfonianu imatynibu i sposób jej otrzymywania
MXPA06015237A (es) 2004-06-29 2007-12-10 Amgen Inc Pirrolo[2-3-d]pirimidinas que modulan la actividad de ack1 y lck.
MX2007001399A (es) * 2004-08-02 2007-04-18 Osi Pharm Inc Compuestos que inhiben pirrolopirimidina multi-cinasa aril-amino sustituidas.
US8211929B2 (en) 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US20060275365A1 (en) * 2005-06-07 2006-12-07 Thomas Backensfeld Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl) [4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
US20070059359A1 (en) * 2005-06-07 2007-03-15 Thomas Backensfeld Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
DE602006015994D1 (de) * 2005-06-23 2010-09-16 Novartis Ag Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer
WO2007076035A2 (en) * 2005-12-21 2007-07-05 Abbott Laboratories Anti-viral compounds
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
ATE541844T1 (de) * 2005-12-21 2012-02-15 Abbott Lab Antivirale verbindungen
EP2397138B1 (en) * 2006-04-20 2013-12-11 Janssen Pharmaceutica NV Aromatic amide derivatives as C-KIT kinase inhibitors
AU2007269540B2 (en) * 2006-07-05 2013-06-27 Exelixis, Inc. Methods of using IGF1R and Abl kinase modulators
EP2094276A4 (en) 2006-12-20 2011-01-05 Abbott Lab ANTIVIRAL COMPOUNDS
WO2008083491A1 (en) 2007-01-11 2008-07-17 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
US20080248548A1 (en) * 2007-04-09 2008-10-09 Flynn Daniel L Modulation of protein functionalities
MX2010003200A (es) * 2007-09-25 2010-04-30 Teva Pharma Composiciones de imatibnib estables.
US8466151B2 (en) * 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
KR20100116607A (ko) 2008-01-11 2010-11-01 낫코 파마 리미티드 항암제로서의 신규한 피라졸로[3,4-ｄ]피리미딘 유도체
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
JP2011523646A (ja) 2008-05-21 2011-08-18 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのリン誘導体
EP3023426A1 (en) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
EP2381777A4 (en) 2008-12-12 2012-08-08 Ariad Pharma Inc AZAINDOL DERIVATIVES AS KINASEHEMMER
ITRM20090578A1 (it) * 2009-11-10 2011-05-11 Noi Per Voi Onlus Nuove composizioni per il trattamento di leucemie chemioresistenti e/o di leucemie potenzialmente chemioresistenti.
WO2011120153A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
TR201010618A2 (tr) * 2010-12-20 2012-07-23 Bi̇lgi̇ç Mahmut İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
PL394169A1 (pl) 2011-03-09 2012-09-10 Adamed Spółka Z Ograniczoną Odpowiedzialnością Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
AU2013223749A1 (en) 2012-02-21 2014-09-11 Sun Pharmaceutical Industries Limited Stable dosage forms of imatinib mesylate
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
EP4772247A2 (en) 2013-08-14 2026-07-08 Novartis AG Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer
WO2017078647A1 (en) 2015-11-05 2017-05-11 Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi Pharmaceutical compositions of imatinib
EP3257499A1 (en) 2016-06-17 2017-12-20 Vipharm S.A. Process for preparation of imatinib methanesulfonate capsules
WO2020152629A1 (en) 2019-01-23 2020-07-30 Novartis Ag New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
US20030069174A1 (en) * 1997-03-10 2003-04-10 Ludwig Pichler Use of human alpha1-acid glycoprotein for producing a pharmaceutical preparation
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
AU6014900A (en) * 1999-07-13 2001-01-30 Kyowa Hakko Kogyo Co. Ltd. Staurosporin derivatives
OA12118A (en) * 1999-12-10 2006-05-04 Pfizer Prod Inc PyrroloÄ2,3-dÜpyrimidine compounds.

Also Published As

Publication number Publication date
ATE432069T1 (de) 2009-06-15
US20090221519A1 (en) 2009-09-03
WO2001047507A3 (en) 2002-04-04
DE60042283D1 (de) 2009-07-09
PE20010991A1 (es) 2001-10-23
CA2394944A1 (en) 2001-07-05
EP1250140A2 (en) 2002-10-23
CN1414858A (zh) 2003-04-30
US20030125343A1 (en) 2003-07-03
JP2003523325A (ja) 2003-08-05
AU2171901A (en) 2001-07-09
ITMI992711A1 (it) 2001-06-27
ES2326307T3 (es) 2009-10-07
ITMI992711A0 (it) 1999-12-27
EP1250140B1 (en) 2009-05-27
AR030179A1 (es) 2003-08-13
CO5271710A1 (es) 2003-04-30
HK1050993A1 (zh) 2003-07-18
CN1304005C (zh) 2007-03-14
WO2001047507A2 (en) 2001-07-05
PT1250140E (pt) 2009-08-24
TWI246917B (en) 2006-01-11

Similar Documents

Publication Publication Date Title
CO5271710A1 (es) Combinanciones de un inhibidor de cinasa de tirosina receptora con un compuesto organico capaz de enlazarse con glicorpoteina acido-a
BR0008365A (pt) 2-amino-6-anilino-purinas e o seu uso comomedicamento
BR0315912A (pt) Compostos pirimìdicos com atividade antiproliferativa (ii)
BRPI0412343A (pt) derivados de piridazina e seu uso como agentes terapêuticos
BRPI0407834A (pt) composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
BRPI0413580A (pt) composto, composição farmacêutica, e, métodos para tratar ou prevenir cáncer em um mamìfero em necessidade de tal tratamento, para modular a formação do fuso mitótico e para inibir a cinesina mitótica ksp
BRPI0413582A (pt) compostos, composições e métodos para inibir a atividade de proteasome
BR0010524A (pt) Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
BRPI0515446A (pt) amidas bicìclicas como inibidores de cinases
BR0109850A (pt) Produto terapêutico de combinação, composição farmacêutica, uso de um produto terapêutico de combinação, e, método para o tratamento ou profilaxia de câncer de próstata
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BR9915210A (pt) N-aril-amidas de ácido antranìlico-e ácido tioantranìlico
BRPI0612845A8 (pt) composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador
BRPI0413255A (pt) uso de uma combinação de um inibidor de quinase do receptor do fator de crescimento epidérmico e agentes citotóxicos para tratamento e inibição do cáncer
BRPI0515477A (pt) derivados heterocìclicos bicìclicos e o uso dos mesmos como inibidores de estaroil-coa-desaturase (scd)
BRPI0411295A (pt) compostos e seu uso na terapia
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BRPI0515488A (pt) derivados de heterocìclicos e seu uso como agentes terapêuticos
BR0213233A (pt) Alcinos inibidores de metaloproteinase de matriz
BR9609503A (pt) Composto, uso de um composto, processo de tratamento de condições onde a inibição de pde especìfico para cgmp é de benefìcio terapêutico, em corpo de animal humano ou não humano, composição farmacêutica, e processos para preparar a mesma e um composto
GT199800150A (es) Derivados de resorcinol.
BR0015532A (pt) Compostos
BRPI0415395A (pt) composto, métodos para inibir a atividade da proteìna quinase e para tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase, e, composição
BR0315988A (pt) Derivados de diidropirimido[4,5-d]pirimidinona substituìda por amino, sua produção e uso como agentes farmacêuticos

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT: A61K 31/7048, A61K 31/495, A61K 35/00, A61P 35/00

Ipc: A61K 31/00 (2009.01)

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 13, 24 E 25 DA LPI.

B15V Prolongation of time limit allowed

Free format text: RECONHECIDO O OBSTACULO ADMINISTRATIVO E DEVOLVIDO O PRAZO DE 19 DIAS, NOS TERMOS DO ARTIGO 221 PARAGRAFO 2O DA LPI E DA RESOLUCAO 116/04.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]